What are the potential risks of using ivermectin for COVID-19 treatment in pregnant women?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Was this fact-check helpful?
1. Summary of the results
The potential risks of using ivermectin for COVID-19 treatment in pregnant women are a subject of ongoing debate and research. According to a systematic review and meta-analysis, there is insufficient evidence to conclude on the safety profile of ivermectin during pregnancy [1]. Another study suggests that ivermectin administration during pregnancy may pose risks, including increased malformations in mice and the impact of P-glycoprotein deficiency on fetal development, based on animal data [2]. However, some researchers propose a three-pronged approach to build a robust evidence base for the use of ivermectin in pregnancy, highlighting the need for further research to inform public health policies [3]. Additionally, the exclusion of pregnant women from COVID-19 clinical trials, including those for ivermectin, has been noted as a significant concern [4]. A separate study found no statistically significant differences in efficacy between ivermectin and placebo groups for COVID-19 treatment, but confirmed the safety of ivermectin at a dose of 0.3-0.4 mg/kg, including for minor participants aged 12 and above [5].
2. Missing context/alternative viewpoints
Some key points that are missing from the original statement include the importance of inclusion of pregnant women in COVID-19 treatment trials, which is crucial for the development of safe and effective therapies [4]. Another crucial aspect is the need for further research to inform public health policies, as the current evidence base is insufficient to support the safety of ivermectin administration during pregnancy [6]. Furthermore, the potential benefits of ivermectin treatment for pregnant women should be considered, as proposed by some researchers [3]. The animal data raising concerns for pregnant women should also be taken into account, including increased malformations in mice and the impact of P-glycoprotein deficiency on fetal development [2]. The safety of ivermectin at a dose of 0.3-0.4 mg/kg is another important consideration, as confirmed by a separate study [5]. Key stakeholders who may benefit from these alternative viewpoints include:
- Pregnant women who may require COVID-19 treatment
- Researchers who are working to develop safe and effective therapies for pregnant women
- Public health policymakers who need to make informed decisions about the use of ivermectin during pregnancy
- Pharmaceutical companies that may be developing ivermectin-based treatments for COVID-19.
3. Potential misinformation/bias in the original statement
The original statement may be biased towards highlighting the potential risks of using ivermectin for COVID-19 treatment in pregnant women, without fully considering the potential benefits of ivermectin treatment [3]. Additionally, the statement may be based on insufficient evidence, as noted by several studies [1] [6] [2]. The exclusion of pregnant women from COVID-19 clinical trials, including those for ivermectin, may also be a source of bias [4]. Key stakeholders who may benefit from this framing include:
- Researchers who are working to develop alternative treatments for COVID-19
- Pharmaceutical companies that may be developing competing treatments for COVID-19
- Public health policymakers who may be hesitant to approve the use of ivermectin during pregnancy due to concerns about safety.